Startups
Neurogene
New York, New York, United States · Houston, Texas, United States
Clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its EXACT platform uses microRNA-based circuits to regulate transgene expression and address overexpression toxicity. Its lead investigational AAV gene therapy, NGN-401 for Rett syndrome, is being evaluated in the Embolden registrational trial. It operates an in-house gene therapy manufacturing facility in Houston and became publicly traded on Nasdaq as NGNE following its December 2023 reverse merger with Neoleukin Therapeutics.
Founded 2018
Team
 Andrew MulbergSenior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control |
 Christine MikailPresident and Chief Financial Officer · Board Member |
 Christy ShaferChief Commercial Officer |
Cory FreedlandBoard Member |
 Donna M. CochenerSenior Vice President and General Counsel |
 Julie JordanChief Medical Officer |
Keith WoodsBoard Member |
 Rachel McMinnFounder and Chief Executive Officer · Executive Chair of the Board |
 Ricardo JimenezSenior Vice President, Technical Operations |
Robert BaffiBoard Member |
 Rohan PalekarBoard Member |
Sarah B. NoonbergBoard Member |
 Stuart CobbChief Scientific Officer |